TheraVet Announces the Commercial Launch of a Local and Sustained Antibiotic Releasing Bone Substitute

31 May 2023 07:30 CEST

• BIOCERA-VET COMBO-CLEAN, a unique bone substitute for antibiotic delivery:
  • combinable with all main antibiotics covering the usual germs involved in bone infections,
  • providing sustained antibiotic delivery for up to 30 days above MIC¹ and,
  • unique osteo-conductive & osteo-integrative properties
• First successful case already reported

Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the commercial launch of BIOCERA-VET^® Combo-Clean, a new reference for BIOCERA-VET, its comprehensive bone substitutes range, in Europe and United Kingdom. BIOCERA-VET ^® Combo-Clean will be available on our website (www.bioceravet.com).

Infections can be a major concern when it comes to orthopedic surgeries and can occur in 5% of these surgeries. In order to prevent damage to the bone, a treatment with antibiotics and removal of infected implants and materials is generally recommended. Also, preventive treatment can occur for high-risk surgeries (e.g., open fracture from a trauma or bite).

BIOCERA-VET^® Combo-Clean is the solution to bring locally high concentration of antibiotics and to ensure stability thanks to its mechanical strength. To manage bone infections, it can be mixed with the 7 most commonly used antibiotics (covering all the most common germs involved in bone infection). In addition to its properties as bone substitute (i.e., mechanical strength, osteointegration and osteoconduction), and superior ergonomics (i.e., easy-to-prepare, highly injectable), BIOCERA-VET^® Combo-Clean features optimal antibiotic release profile enabling a local but also long-lasting antimicrobial action for up to 30 days.

The combination of all these properties makes of BIOCERA-VET^® Combo-Clean the first-of-its-kind sustained antibiotic releasing bone substitute.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth^® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.

For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter

About BIOCERA-VET

In close collaboration with an international scientific board, THERAVET^® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET^®. BIOCERA-VET^® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

BIOCERA-VET^® is declined in different lines:

• BIOCERA-VET^® BONE SURGERY RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement
• BIOCERA-VET^® SMARTGRAFT, a naturally osteoconductive bone graft
• BIOCERA-VET^® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
• BIOCERA-VET^® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty
• BIOCERA-VET^® COMBO-CLEAN, a local and long-lasting antibiotic delivery calcium-phosphate bone substitute

For more information, visit BIOCERA-VET website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005461/en/

TheraVet
Chief Operating Officer
Sabrina Ena
investors@thera.vet
Tel: +32 (0) 71 96 00 43

Chief Corporate Officer
Julie Winand
investors@thera.vet

NewCap
Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15

NewCap Belgique
Press Relations
Laure-Eve Monfort
lemonfort@thera.vet
Tel: + 32 (0) 489 57 76 52